Shares of BriaCell Therapeutics Corp. (CVE:BCT – Get Free Report) fell 3.8% during mid-day trading on Tuesday . The stock traded as low as C$10.60 and last traded at C$10.60. Approximately 3,402 shares were traded during trading, a decline of 73% from the average session volume of 12,671 shares. The stock had previously closed at C$11.02.
BriaCell Therapeutics Stock Down 3.8%
The business has a 50 day simple moving average of C$10.60 and a 200 day simple moving average of C$10.60. The company has a debt-to-equity ratio of 0.05, a current ratio of 129.63 and a quick ratio of 128.68. The company has a market capitalization of C$168.68 million and a price-to-earnings ratio of -28.19.
About BriaCell Therapeutics
BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing approaches for the management of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test.
Recommended Stories
- Five stocks we like better than BriaCell Therapeutics
- Running on Empty: 3 Energy Plays for Europe’s Deep Freeze
- 3 Healthcare Stocks for 3 Stages of Life
- Curaleaf Tries To Roll Up Aurora In a Hostile Cannabis Bid
- MarketBeat’s Most Downgraded Stocks in Q3: 2 Look Cheap, 1 Looks Risky
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
